Champlain Investment Partners LLC Has $114.97 Million Stock Holdings in Agilent Technologies, Inc. $A

Clinical OMICsEngineered Islets Could Eliminate Need for Immunosuppression in Type 1 Diabetes

FierceBiotechUnlocking Unstructured Data with AI for Optimized Protocol Development

Endpoints NewsBristol Myers turns focus to AI costs after broad rollout to workers

Clinical OMICsNew Tumor Survival Mechanism Revealed in Aggressive ALT Cancers

Clinical OMICsVeracyte Launches Test Identifying Breast Cancer Patients Who Don’t Need Chemo

Endpoints NewsAxsome pushes back generic entry for narcolepsy drug until 2040

Clinical OMICsNanotube Sensor Provides Chemical Imaging for Earlier Detection of Bladder Cancer Recurrence

Endpoints NewsFDA guides pharma on explaining unapproved drugs to payors

Clinical OMICsAI Model Predicts Radiation Uptake Before Treatment in Advanced Prostate Cancer

BioWorldAppointments and advancements for June 3, 2026

BioWorldFinancings for June 3, 2026

BioWorldIn the clinic for June 3, 2026